ZA200006308B - Improved in vivo production of cephalosporins. - Google Patents

Improved in vivo production of cephalosporins. Download PDF

Info

Publication number: ZA200006308B
Authority: ZA; South Africa
Prior art keywords: expandase; dna fragment; host cell; host; apa
Prior art date: 1998-05-19

Application number

ZA200006308A

Other languages

English (en)

Inventor

Maarten Nieboer

Roelof Ary Lans Bovenberg

Original Assignee

Dsm Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-19

Filing date

2000-11-03

Publication date

2001-05-23

2000-11-03 Application filed by Dsm Nv filed Critical Dsm Nv

2001-05-23 Publication of ZA200006308B publication Critical patent/ZA200006308B/en

Links

150000001780 cephalosporins Chemical class 0.000 title abstract description 30
238000004519 manufacturing process Methods 0.000 title abstract description 24
238000001727 in vivo Methods 0.000 title abstract description 6
229930186147 Cephalosporin Natural products 0.000 title description 28
229940124587 cephalosporin Drugs 0.000 title description 28
101710104123 Deacetoxycephalosporin C synthase Proteins 0.000 claims abstract description 108
210000004027 cell Anatomy 0.000 claims abstract description 57
238000000034 method Methods 0.000 claims abstract description 40
210000002500 microbody Anatomy 0.000 claims abstract description 39
210000000172 cytosol Anatomy 0.000 claims abstract description 29
239000012634 fragment Substances 0.000 claims description 43
241000228150 Penicillium chrysogenum Species 0.000 claims description 38
-1 beta-lactam compound Chemical class 0.000 claims description 21
230000008685 targeting Effects 0.000 claims description 21
238000012986 modification Methods 0.000 claims description 17
230000004048 modification Effects 0.000 claims description 17
241000233866 Fungi Species 0.000 claims description 16
241000187433 Streptomyces clavuligerus Species 0.000 claims description 13
239000002773 nucleotide Substances 0.000 claims description 13
125000003729 nucleotide group Chemical group 0.000 claims description 13
210000004899 c-terminal region Anatomy 0.000 claims description 10
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
244000005700 microbiome Species 0.000 claims description 9
235000004400 serine Nutrition 0.000 claims description 9
230000009466 transformation Effects 0.000 claims description 8
241000228431 Acremonium chrysogenum Species 0.000 claims description 6
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims description 5
241000228143 Penicillium Species 0.000 claims description 5
235000004279 alanine Nutrition 0.000 claims description 5
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
125000000539 amino acid group Chemical group 0.000 claims description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
235000003704 aspartic acid Nutrition 0.000 claims description 3
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 2
241000351920 Aspergillus nidulans Species 0.000 claims description 2
241000228245 Aspergillus niger Species 0.000 claims description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
235000018417 cysteine Nutrition 0.000 claims description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
230000001131 transforming effect Effects 0.000 claims description 2
NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 claims 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
125000003460 beta-lactamyl group Chemical group 0.000 claims 1
102000004190 Enzymes Human genes 0.000 abstract description 47
108090000790 Enzymes Proteins 0.000 abstract description 47
210000002824 peroxisome Anatomy 0.000 abstract description 12
230000000694 effects Effects 0.000 abstract description 5
108020004414 DNA Proteins 0.000 description 36
108090000623 proteins and genes Proteins 0.000 description 19
229930182555 Penicillin Natural products 0.000 description 18
150000001413 amino acids Chemical class 0.000 description 12
150000002960 penicillins Chemical class 0.000 description 12
230000004807 localization Effects 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
101150091913 cefE gene Proteins 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
238000000855 fermentation Methods 0.000 description 8
230000004151 fermentation Effects 0.000 description 8
239000002609 medium Substances 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 7
229940024606 amino acid Drugs 0.000 description 7
230000008569 process Effects 0.000 description 7
NVIAYEIXYQCDAN-MHTLYPKNSA-N (6r,7s)-7-azaniumyl-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S1CC(C)=C(C([O-])=O)N2C(=O)[C@H]([NH3+])[C@@H]12 NVIAYEIXYQCDAN-MHTLYPKNSA-N 0.000 description 6
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
229940049954 penicillin Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 6
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000006049 ring expansion reaction Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102000057234 Acyl transferases Human genes 0.000 description 4
108700016155 Acyl transferases Proteins 0.000 description 4
241000187390 Amycolatopsis lactamdurans Species 0.000 description 4
MIFYHUACUWQUKT-UHFFFAOYSA-N Isopenicillin N Natural products OC(=O)C1C(C)(C)SC2C(NC(=O)CCCC(N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-UHFFFAOYSA-N 0.000 description 4
108010085186 Peroxisomal Targeting Signals Proteins 0.000 description 4
229950008644 adicillin Drugs 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
230000035772 mutation Effects 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
210000001938 protoplast Anatomy 0.000 description 4
239000013598 vector Substances 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
241000589516 Pseudomonas Species 0.000 description 3
241000228417 Sarocladium strictum Species 0.000 description 3
241000187747 Streptomyces Species 0.000 description 3
239000001361 adipic acid Substances 0.000 description 3
235000011037 adipic acid Nutrition 0.000 description 3
230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
108010005802 desacetoxycephalosporin C synthetase Proteins 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
KINULKKPVJYRON-PVNXHVEDSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine;hydron;dichloride Chemical compound Cl.Cl.N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 KINULKKPVJYRON-PVNXHVEDSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
150000003952 β-lactams Chemical class 0.000 description 3
ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108700005088 Fungal Genes Proteins 0.000 description 2
101710107944 Isopenicillin N synthase Proteins 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001493 electron microscopy Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 description 2
230000014726 immortalization of host cell Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
229940056360 penicillin g Drugs 0.000 description 2
230000000858 peroxisomal effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
235000013619 trace mineral Nutrition 0.000 description 2
239000011573 trace mineral Substances 0.000 description 2
238000000844 transformation Methods 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
VQDJODAWOFNASI-UHFFFAOYSA-N 2-propylpropanedioic acid Chemical compound CCCC(C(O)=O)C(O)=O VQDJODAWOFNASI-UHFFFAOYSA-N 0.000 description 1
NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical group C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 1
QIMWXHQLMOKTMT-UHFFFAOYSA-N 5-oxo-5-sulfanylpentanoic acid Chemical compound OC(=O)CCCC(S)=O QIMWXHQLMOKTMT-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
241001619326 Cephalosporium Species 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
101100385455 Escherichia coli (strain K12) cspE gene Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930191709 Isopenicillin Natural products 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
108010073038 Penicillin Amidase Proteins 0.000 description 1
229930195708 Penicillin V Natural products 0.000 description 1
101000847770 Penicillium chrysogenum N-(5'-phosphoribosyl)anthranilate isomerase Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000589746 Pseudomonas sp. SE83 Species 0.000 description 1
GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
101000981089 Streptomyces clavuligerus Deacetoxycephalosporin C synthase Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
CSGFFYNMTALICU-ZWNOBZJWSA-N adipyl-7-aminodesacetoxycephalosporanic acid Natural products CC1=C(N2[C@H](SC1)[C@H](NC(=O)CCCCC(O)=O)C2=O)C(O)=O CSGFFYNMTALICU-ZWNOBZJWSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
229940106164 cephalexin Drugs 0.000 description 1
UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
238000012993 chemical processing Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
NNQIJOYQWYKBOW-JWKOBGCHSA-N deacetoxycephalosporin C Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 NNQIJOYQWYKBOW-JWKOBGCHSA-N 0.000 description 1
230000020176 deacylation Effects 0.000 description 1
238000005947 deacylation reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical group ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
101150073906 gpdA gene Proteins 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
239000000203 mixture Substances 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
101150074325 pcbC gene Proteins 0.000 description 1
WSHJJCPTKWSMRR-RXMQYKEDSA-N penam group Chemical group S1CCN2[C@H]1CC2=O WSHJJCPTKWSMRR-RXMQYKEDSA-N 0.000 description 1
229940056367 penicillin v Drugs 0.000 description 1
BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000013587 production medium Substances 0.000 description 1
230000001915 proofreading effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
229960004295 valine Drugs 0.000 description 1
238000012795 verification Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Cephalosporin Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200006308A 1998-05-19 2000-11-03 Improved in vivo production of cephalosporins. ZA200006308B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98201655		1998-05-19

Publications (1)

Publication Number	Publication Date
ZA200006308B true ZA200006308B (en)	2001-05-23

Family

ID=8233737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200006308A ZA200006308B (en)	1998-05-19	2000-11-03	Improved in vivo production of cephalosporins.

Country Status (16)

Country	Link
US (2)	US6995003B1 (id)
EP (2)	EP1078069B1 (id)
JP (1)	JP2003527069A (id)
KR (1)	KR100648480B1 (id)
CN (2)	CN100390285C (id)
AT (1)	ATE386123T1 (id)
AU (1)	AU4144999A (id)
BR (1)	BR9910532A (id)
DE (1)	DE69938129D1 (id)
ES (1)	ES2302379T3 (id)
ID (1)	ID27054A (id)
MX (1)	MXPA00011223A (id)
PL (1)	PL344863A1 (id)
RU (1)	RU2230790C2 (id)
WO (1)	WO1999060102A2 (id)
ZA (1)	ZA200006308B (id)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0011185D0 (en) *	2000-05-09	2000-06-28	Synpac Pharmaceuticals Limited	Protein
CN1796537B (zh) *	2004-12-23	2010-09-08	华北制药集团有限责任公司	一种新的产黄青霉菌株以及利用此菌株发酵制备青霉素
US20060217971A1 (en) *	2005-03-28	2006-09-28	Tellabs Operations, Inc.	Method and apparatus for modifying an encoded signal
WO2009065777A1 (en)	2007-11-20	2009-05-28	Dsm Ip Assets B.V.	Dicarboxylic acid production in a filamentous fungus
BRPI0819717B1 (pt)	2007-11-20	2022-05-17	Dsm Ip Assets B.V.	Levedura recombinante e processo para a produção de ácido succínico
ATE555203T1 (de)	2007-11-20	2012-05-15	Dsm Ip Assets Bv	Dicarbonsäureproduktion in eukaryonten
EP2116136A1 (en)	2008-05-08	2009-11-11	Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO	Novel phytases
US8735100B2 (en)	2009-03-17	2014-05-27	Nederlandse Organisatie Voor Toegepast -Natuurwetenschappelijk Onderzoek Tno	Cellulose and ligno-cellulose active proteins
WO2010118932A1 (en)	2009-04-15	2010-10-21	Dsm Ip Assets B.V.	Dicarboxylic acid production process
UA108853C2 (uk)	2009-07-10	2015-06-25		Спосіб ферментації галактози
AR081827A1 (es)	2010-04-21	2012-10-24	Dsm Ip Assets Bv	Proceso para producir celulas capaces de convertir arabinosa
EP2388331A1 (en)	2010-05-21	2011-11-23	Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO	Constitutive promoter
CN103154234B (zh)	2010-10-13	2016-08-17	帝斯曼知识产权资产管理有限公司	发酵戊糖和葡萄糖的酵母细胞
EP2699589A2 (en)	2011-04-22	2014-02-26	DSM IP Assets B.V.	Yeast cell capable of converting sugars including arabinose and xylose
EP2554668A1 (en)	2011-08-04	2013-02-06	DSM IP Assets B.V.	A pentose sugar fermenting cell
AR087423A1 (es)	2011-08-04	2014-03-19	Dsm Ip Assets Bv	Celula capaz de fermentar azucares pentosas
AU2013211605B2 (en)	2012-01-23	2017-04-06	Dsm Ip Assets B.V.	Diterpene production
US10273507B2 (en)	2012-10-16	2019-04-30	Dsm Ip Assets B.V.	Cells with improved pentose conversion
EP2772545A1 (en)	2013-03-01	2014-09-03	Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO	Starch active proteins
WO2014161988A1 (en)	2013-04-05	2014-10-09	Université Du Luxembourg	Biotechnological production of itaconic acid
MX2015015274A (es)	2013-05-02	2016-05-26	Dutch Dna Biotech B V	Ruta de ácido organico novedosa.
US10689681B2 (en)	2013-05-31	2020-06-23	Dsm Ip Assets B.V.	Microorganisms for diterpene production
EP3021689B1 (en)	2013-07-15	2021-03-24	DSM IP Assets B.V.	Diterpene production
AU2014298420B2 (en)	2013-07-31	2018-10-04	Dsm Ip Assets B.V.	Recovery of steviol glycosides
CN107429273A (zh)	2015-02-16	2017-12-01	帝斯曼知识产权资产管理有限公司	用于在厌氧条件下生产衣康酸的方法
CA2979931A1 (en)	2015-03-16	2016-09-22	Dsm Ip Assets B.V.	Udp-glycosyltransferases
US20180057850A1 (en)	2015-03-23	2018-03-01	Dsm Ip Assets B.V.	Udp-glycosyltransferases from solanum lycopersicum
EP3718417B1 (en)	2015-04-03	2025-09-03	DSM IP Assets B.V.	Steviol glycosides
US11332724B2 (en)	2015-04-21	2022-05-17	Dsm Ip Assets B.V.	Microbial production of terpenoids
US11319543B2 (en)	2015-05-22	2022-05-03	Dsm Ip Assets B.V.	Acetate consuming yeast cell
BR112018000550B1 (pt)	2015-07-10	2022-05-10	Dsm Ip Assets B.V.	Método para preparar uma composição de glicosídeo de esteviol
US20180230505A1 (en)	2015-08-13	2018-08-16	Dsm Ip Assets B.V.	Steviol glycoside transport
WO2017050652A1 (en)	2015-09-25	2017-03-30	Dsm Ip Assets B.V.	Asparaginase
CA2999638A1 (en)	2015-10-05	2017-04-13	Dsm Ip Assets B.V.	Kaurenoic acid hydroxylases
WO2017060195A1 (en)	2015-10-06	2017-04-13	Dsm Ip Assets B.V.	Eukaryotic cell with increased production of fermentation product
CA3010288A1 (en)	2015-12-30	2017-07-06	Dsm Ip Assets B.V.	Partial enzymatic hydrolysis of triacylglycerols
CN108884480A (zh)	2015-12-30	2018-11-23	帝斯曼知识产权资产管理有限公司	三酰基甘油的部分酶水解
WO2017167849A1 (en)	2016-03-31	2017-10-05	Dsm Ip Assets B.V.	Enzyme composition and preparation of a dairy product with improved properties
WO2017167847A1 (en)	2016-03-31	2017-10-05	Dsm Ip Assets B.V.	Production of milk with low lactose content
WO2017167848A1 (en)	2016-03-31	2017-10-05	Dsm Ip Assets B.V.	Enzyme composition and preparation of a dairy product with improved properties
CN109312296B (zh)	2016-06-14	2023-05-05	帝斯曼知识产权资产管理有限公司	重组酵母细胞
CN109689864B (zh)	2016-07-13	2023-04-04	帝斯曼知识产权资产管理有限公司	苹果酸脱氢酶
BR112019002417B1 (pt)	2016-08-09	2023-05-02	Dsm Ip Assets B.V.	Cristalização de glicosídeos de esteviol
BR112019002432A2 (pt)	2016-08-09	2019-06-04	Dsm Ip Assets Bv	cristalização de glicosídeos de esteviol
CN110036114B (zh)	2016-08-26	2023-09-29	勒萨弗尔公司	提高的衣康酸生产
WO2018073107A1 (en)	2016-10-19	2018-04-26	Dsm Ip Assets B.V.	Eukaryotic cell comprising xylose isomerase
BR112019008237A2 (pt)	2016-10-27	2019-07-16	Dsm Ip Assets Bv	geranilgeranil pirofosfato sintases
JP2020500520A (ja)	2016-12-08	2020-01-16	ディーエスエムアイピーアセッツビー．ブイ．ＤｓｍＩｐＡｓｓｅｔｓＢ．Ｖ．	カウレン酸ヒドロキシラーゼ
WO2018114940A1 (en)	2016-12-21	2018-06-28	Dsm Ip Assets B.V.	Lipolytic enzyme variants
WO2018114912A1 (en)	2016-12-21	2018-06-28	Dsm Ip Assets B.V.	Lipolytic enzyme variants
WO2018114938A1 (en)	2016-12-21	2018-06-28	Dsm Ip Assets B.V.	Lipolytic enzyme variants
WO2018114941A1 (en)	2016-12-21	2018-06-28	Dsm Ip Assets B.V.	Lipolytic enzyme variants
WO2018114995A1 (en)	2016-12-22	2018-06-28	Dsm Ip Assets B.V.	Fermentation process for producing steviol glycosides
EP3638770B1 (en)	2017-06-13	2023-01-18	DSM IP Assets B.V.	Recombinant yeast cell
EP3645714B1 (en)	2017-06-27	2022-08-31	DSM IP Assets B.V.	Udp-glycosyltransferases
EP3688177A1 (en)	2017-09-26	2020-08-05	DSM IP Assets B.V.	Acetic acid consuming strain
EP3533878A1 (en)	2018-02-28	2019-09-04	Dutch DNA Biotech B.V.	Process for producing citramalic acid employing aspergillus
BR112020025589A2 (pt)	2018-06-19	2021-03-23	Dsm Ip Assets B.V.	variantes de enzima lipolítica
AU2021367159A1 (en)	2020-10-22	2023-05-04	Cargill, Incorporated	Microorganisms for diterpene production
AU2022297881A1 (en)	2021-06-24	2024-01-18	Fonterra Co-Operative Group Limited	Recombinant beta-lactoglobulin
WO2023285280A1 (en)	2021-07-12	2023-01-19	Dsm Ip Assets B.V.	Recombinant yeast cell
CN117916381A (zh)	2021-07-12	2024-04-19	丹尼斯科美国公司	重组酵母细胞
US20250283121A1 (en)	2021-07-12	2025-09-11	Danisco Us Inc.	Recombinant yeast cell
MX2024000606A (es)	2021-07-12	2024-01-30	Danisco Us Inc	Celula de levadura recombinante.
WO2023285282A1 (en)	2021-07-12	2023-01-19	Dsm Ip Assets B.V.	Recombinant yeast cell
WO2023285297A1 (en)	2021-07-12	2023-01-19	Dsm Ip Assets B.V.	Recombinant yeast cell
WO2023079050A1 (en)	2021-11-04	2023-05-11	Dsm Ip Assets B.V.	Recombinant yeast cell
US20240409965A1 (en)	2021-11-04	2024-12-12	Danisco Us Inc.	Variant polypeptide and recombinant yeast cell
WO2023079048A1 (en)	2021-11-04	2023-05-11	Dsm Ip Assets B.V.	Process for the production of ethanol and recombinant yeast cell
EP4430174A1 (en)	2021-11-09	2024-09-18	Amgen Inc.	Production of therapeutic proteins
US20250304938A1 (en)	2022-05-16	2025-10-02	Dsm Ip Assets B.V.	Lipolytic enzyme variants
WO2024218244A1 (en)	2023-04-20	2024-10-24	Dsm Ip Assets B.V.	Strains and methods for the production of mogrosides
WO2025012325A1 (en)	2023-07-11	2025-01-16	Dsm Ip Assets B.V.	Protein arginine deiminase
WO2025144795A1 (en)	2023-12-28	2025-07-03	Dsm Ip Assets B.V.	Cells and methods for the production of glycosylated compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4003894A (en)	1971-08-17	1977-01-18	Gist-Brocades N.V.	Preparation of 7-substituted amino-desacetoxycephalosporanic acid compounds
PT83746B (pt)	1985-11-15	1988-08-17	Gist Brocades Nv	Processo para a preparacao de novos biocatalisadores imobilizados e para a producao de etanol por fermentacao
US5070020A (en)	1988-05-09	1991-12-03	Eli Lilly And Company	Recombinant dna expression vectors and dna compounds that encode deacetoxycephalosporin c synthetase
US5082772A (en)	1988-10-24	1992-01-21	Eli Lilly And Company	Process for preparing deacetylcephalosporin c
PT97116B (pt)	1990-03-23	1998-10-30	Gist Brocades Nv	Processo para modular a producao de metabolitos secundarios nomeadamente derivados de beta-lactama
US5318896A (en) *	1991-09-11	1994-06-07	Merck & Co., Inc.	Recombinant expandase bioprocess for preparing 7-aminodesacetoxy cephalosporanic acid (7-ADCA)
KR100227711B1 (ko) *	1991-10-15	1999-12-01	한스 발터 라벤	7-아미노세팔로스포란산 및 7-아미노데아세틸세팔로스포란산 제조를 위한 신규한 생물학적 공정
DE69432543T2 (de)	1993-07-23	2003-12-24	Dsm N.V., Te Heerlen	Selektionmarker-genfreie rekombinante Stämme: Verfahren zur ihrer Herstellung und die Verwendung dieser Stämme
ES2194873T3 (es) *	1993-07-30	2003-12-01	Dsm Ip Assets Bv	Procedimiento para la produccion eficaz de 7-adca a traves de 3-(carboxietil)propionil-7-adca.
BR9407108A (pt)	1993-07-30	1996-08-27	Gist Brocades Nv	Processo para a preparação e recuperação de ácido 7-amino desacetoxi cefalosporânico (7-adca) vetor de ADN recombinante e célula hospedeira transformada com um vetor definido
GB2323361A (en) *	1995-11-27	1998-09-23	Gist Brocades Bv	Improved process for the production of semi-synthetic cephalosporins via expandase activity on penicillin G
AU4114697A (en)	1996-07-16	1998-02-09	Gist-Brocades B.V.	Improved process for the production of adipoyl cephalosporins

1999
- 1999-05-19 CN CNB998063142A patent/CN100390285C/zh not_active Expired - Lifetime
- 1999-05-19 JP JP2000549710A patent/JP2003527069A/ja not_active Withdrawn
- 1999-05-19 PL PL99344863A patent/PL344863A1/xx not_active Application Discontinuation
- 1999-05-19 US US09/700,080 patent/US6995003B1/en not_active Expired - Fee Related
- 1999-05-19 EP EP99925015A patent/EP1078069B1/en not_active Expired - Lifetime
- 1999-05-19 WO PCT/EP1999/003455 patent/WO1999060102A2/en not_active Ceased
- 1999-05-19 RU RU2000131687/13A patent/RU2230790C2/ru not_active IP Right Cessation
- 1999-05-19 BR BR9910532-2A patent/BR9910532A/pt not_active Application Discontinuation
- 1999-05-19 AT AT99925015T patent/ATE386123T1/de not_active IP Right Cessation
- 1999-05-19 KR KR1020007012957A patent/KR100648480B1/ko not_active Expired - Fee Related
- 1999-05-19 DE DE69938129T patent/DE69938129D1/de not_active Expired - Lifetime
- 1999-05-19 CN CNA2008100875582A patent/CN101353660A/zh active Pending
- 1999-05-19 ES ES99925015T patent/ES2302379T3/es not_active Expired - Lifetime
- 1999-05-19 MX MXPA00011223A patent/MXPA00011223A/es unknown
- 1999-05-19 ID IDW20002338A patent/ID27054A/id unknown
- 1999-05-19 EP EP08101461A patent/EP1953230A1/en not_active Withdrawn
- 1999-05-19 AU AU41449/99A patent/AU4144999A/en not_active Abandoned
2000
- 2000-11-03 ZA ZA200006308A patent/ZA200006308B/en unknown
2006
- 2006-02-07 US US11/349,381 patent/US20060127972A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1999060102A2 (en)	1999-11-25
MXPA00011223A (es)	2002-04-17
CN101353660A (zh)	2009-01-28
ES2302379T3 (es)	2008-07-01
WO1999060102A3 (en)	2000-02-03
US20060127972A1 (en)	2006-06-15
PL344863A1 (en)	2001-11-19
US6995003B1 (en)	2006-02-07
DE69938129D1 (de)	2008-03-27
CN1301303A (zh)	2001-06-27
KR20010025039A (ko)	2001-03-26
BR9910532A (pt)	2001-10-16
EP1078069B1 (en)	2008-02-13
KR100648480B1 (ko)	2006-11-24
CN100390285C (zh)	2008-05-28
EP1953230A1 (en)	2008-08-06
EP1078069A2 (en)	2001-02-28
AU4144999A (en)	1999-12-06
RU2230790C2 (ru)	2004-06-20
ID27054A (id)	2001-02-22
JP2003527069A (ja)	2003-09-16
ATE386123T1 (de)	2008-03-15

Publication	Publication Date	Title
EP1078069B1 (en)	2008-02-13	Improved in vivo production of cephalosporins
KR100336174B1 (ko)	2002-11-01	2-(카르복시에틸티오)아세틸-7-adca및3-(카르복시메틸티오)프로피오닐-7-adca를경유하여7-adca를제조하는효율적인방법
EP0711348B1 (en)	2003-03-19	Process for the efficient production of 7-adca via 3-(carboxyethylthio)propionyl-7-adca
NO315802B1 (no)	2003-10-27	Biologisk fremgangsmåte for fremstilling av 7-ACA og 7-ADAC
JPH0787788B2 (ja)	1995-09-27	イソペニシリンｎ合成酵素をコ−ドしているｄｎａ化合物および組換えｄｎａ発現ベクタ−
MX2007006780A (es)	2007-08-06	Produccion de beta-lactamas en celulas individuales.
Forney et al.	1989	Alteration of the catalytic efficiency of penicillin amidase from Escherichia coli
AU701665B2 (en)	1999-02-04	Process of producing beta-lactam antibiotics applying microorganisms with increased ligase activity
WO1998002551A2 (en)	1998-01-22	Process for the production of adipoyl cephalosporins
EP0444758A1 (en)	1991-09-04	Method for modification of ACV synthetase and use of the modified enzyme for production of beta-lactam antibiotics
HK1036480A (en)	2002-01-04	Improved in vivo production of cephalosporins
EP0716698B1 (en)	2004-09-22	Process for the efficient production of 7-ADCA via 2-(carboxyethylthio)acetyl-7-ADCA and 3-(carboxymethylthio)propionyl-7-ADCA
WO1997038107A1 (en)	1997-10-16	An enzyme with high adipoyl-coenzyme a synthetase activity and uses thereof
RU2139350C1 (ru)	1999-10-10	Способ эффективного производства 7-адцк через 3-(карбоксиэтилтио)пропионил-7-адцк
RU2139349C1 (ru)	1999-10-10	Способ эффективного производства 7-адцк через 2-(карбоксиэтилтио) ацетил-7-адцк и 3-(карбоксиметилтио)пропионил-7-адцк
WO1999001561A1 (en)	1999-01-14	IMPROVED PROCESS FOR THE PRODUCTION OF β-LACTAMS